viewBiocept Inc

Biocept announces Highmark has made a positive coverage determination on Target Selector liquid biopsy

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage for use in the diagnosis and treatment of patients with non-small cell lung cancer. Nall discusses what that means for Patients and also for the company.

Nall also told Proactive about their testing program related to COVID-19 and how many tests they have been able to do.

Quick facts: Biocept Inc

Price: 4.93 USD

Market: NASDAQ
Market Cap: $65.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...


Biocept updates on its coronavirus testing volume and initiatives for the...

Biocept, Inc. (NASDAQ:BIOC) CEO Mike Nall tells Proactive it has received more than 250,000 samples received to date for coronavirus processing through its RT-PCR technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory. Nall says he expects COVID-19 RT-PCR testing...

3 weeks, 3 days ago

2 min read